In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Millennium Chief Medical Officer Nancy Simonian: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

Exec discusses the firm's first year of profitability, the multiple myeloma market and current Velcade strategy following its copromotion deal with J&J.
Advertisement

Related Content

Millennium To Begin Phase III Trial For Velcade As First-Line Treatment For Multiple Myeloma
Millennium To Begin Phase III Trial For Velcade As First-Line Treatment For Multiple Myeloma
J&J’s Doxil Approved For Use With Velcade In Second-Line Multiple Myeloma
Millennium Initiates New Clinical Program For Ulcerative Colitis Candidate
Millennium Chief Medical Officer Nancy Simonian: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
J&J Seeks Approval For Doxil Plus Velcade In Multiple Myeloma
Millennium Inks Velcade Co-Promotion Deal With J&J In U.S.
Millennium Inks Velcade Co-Promotion Deal With J&J In U.S.
Celgene’s Revlimid Approved For Second-Line Multiple Myeloma
Third Time Is The Charm For Thalomid Myeloma Indication

Topics

Advertisement
UsernamePublicRestriction

Register

PS065643

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel